Based upon our findings in this study and previous reports, we hypothesized that co-treatment with GSK126 and taxane can induce robust death even in PTEN-negative cancer cells through increasing FOXO1 expression (by GSK126) and nuclear localization (by taxane) (Figure 5E). The gene discussed is PTEN; the disease is cancer.